{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"33","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Fludarabine Busulfan chemotherapy regimen(Flu-Bu4), followed by allogeneic stem cell transplant from best available, matched donor.\n\nFludarabine/Busulfan x 4 days:\n\nFludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.\n\nBusulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.\n\nThe Fludarabine shall be administered prior to the Busulfan each day.","id":"OG000","title":"Flu-Bu4"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days, one-year","title":"Percentage of Patients With Treatment Related Mortality (TRM)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}